AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 232 min read$ZVRA

Thompson Rahsaan sold $438K of ZVRA

Thompson Rahsaan (Chief Legal & Compliance) sold 34,557 shares of ZEVRA THERAPEUTICS, INC. (ZVRA) at $12.68 ($0.44M total) on 2026-06-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Thompson Rahsaan
Published Jun 23, 2026, 8:16 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 23, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ZVRA
Neutral
medium confidence
Mentioned
$ZVRA
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ZVRANeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale size, price, and post-transaction holdings; it can influence near-term sentiment but does not change fundamentals in the text.

02

Market read

Insider selling under a 10b5-1 plan is usually a low-signal event; any trading impact is likely limited to short-term sentiment.

03

What to watch

Traders may over-weight insider sales; without changes in guidance, trials, or financing, the disclosure is typically sentiment-only.

Relevance 3/10Novelty 5/10Timing: Filed 2026-06-23; sale executed 2026-06-22 (after-hours/next session read-through).

Background

The article is an SEC Form 4 insider transaction filing for ZEVRA THERAPEUTICS, Inc.

Company-level read

Ticker impact

$ZVRANeutralMedium confidence
Context

SEC Form 4 shows Thompson Rahsaan (Chief Legal & Compliance) sold 34,557 ZVRA shares for about $438.3K on 2026-06-22 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this Form 4; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a pre-arranged 10b5-1 open-market sale by an officer, with no accompanying new operational/regulatory/financial information.

Market effects

Sector

Minimal—this is company-specific insider transaction data, not a sector-wide signal.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Because it’s a 10b5-1 plan, the sale may be mechanically scheduled and less informative than discretionary selling.

Key entities

  • issuer
    ZEVRA THERAPEUTICS, INC.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Thompson Rahsaan

    Chief Legal & Compliance officer who sold shares under a pre-arranged 10b5-1 plan.

Read at source← All news

Related articles

AUG 7
$ZVRAMed

Zevra Therapeutics Q2 Earnings Call Highlights

Zevra Therapeutics (NASDAQ:ZVRA) reported Q2 updates on MIPLYFFA, including high refill, compliance and persistence, and payer coverage of 69% of covered lives. Net reimbursements were $9 million. In the EU, Zevra will re-examine arimoclomol after a CHMP negative opinion, with an expected Q4 decision. Cash was $260.2 million.

yahoo.com4 min
AUG 5
$ZVRAMed

ZEVRA THERAPEUTICS, INC. (ZVRA): Results of Operations and Financial Condition

ZEVRA THERAPEUTICS, INC. (ZVRA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 zvra-20260805xex991earnings.htm EX-99.1 Document Exhibit 99.1 Zevra Reports Second Quarter 2026 Financial Results and Corporate Update $39.7 million net revenue for Q2 2026, driven by $30.2 million in revenue from MIPLYFFA 53% increase in total net revenue over Q2 2025

SEC EDGAR 8-K6 min
JUL 24
$ZVRAMedAI 8/10

Zevra Slips on Revealing Opinion on Treatment

Zevra Therapeutics (NASDAQ: ZVRA) fell after the EMA CHMP issued a negative opinion on its marketing authorization application for arimoclomol to treat Niemann-Pick disease type C. Zevra said it will request a re-examination and provide supporting explanations, and it continues expanded access to support eligible patients and gather real-world evidence.

baystreet.ca2 min
JUN 8
$ZVRAMed

Zevra Therapeutics extends MIPLYFFA exclusivity to 2041

Zevra Therapeutics said it filed a patent for MIPLYFFA (arimoclomol) to be listed in the FDA’s Orange Book, with protection extending to 2041. The company said the Orange Book listing would strengthen MIPLYFFA’s exclusivity and could trigger an automatic stay on generic approvals if challenged. Zevra shares rose more than 9.5% on Monday.

proactiveinvestors.com3 min